We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer said it will add participants as young as 12 to the global phase 3 trial of its COVID-19 vaccine candidate to glean more information on how the treatment affects different age groups. Read More
The first participant has been dosed in Vaxart’s phase 1 study of an oral COVID-19 vaccine tablet the company is developing as an alternative to injectable vaccines. If approved, it would be the first-ever vaccine in tablet form. Read More
A clinical trial of Eli Lilly’s antibody candidate treatment for COVID-19 was paused Tuesday following a safety incident — awkward timing as the company has just applied to the FDA for an Emergency Use Authorization (EUA) for the product. Read More
Eli Lilly says its rheumatoid arthritis (RA) therapy Olumiant (baricitinib) combined with Gilead Sciences’ antiviral remdesivir reduced COVID-19 patient recovery time by 12.5 percent, or from eight to seven days, over remdesivir alone. Read More
A late-stage trial of Russia’s Sputnik V COVID-19 neutralizing antibody vaccine is now underway in the United Arab Emirates, the Kremlin said. Read More
The NIH’s National Heart, Lung and Blood Institute (NHLBI) has enrolled the first participants in a multicenter phase 2 trial evaluating Rigel Pharmaceuticals’ oral spleen tyrosine kinase inhibitor fostamatinib as a COVID-19 treatment. Read More